BioCentury | Feb 17, 2014
Analyst Picks & Changes

Analyst picks & changes

...in 2014 and $37M in 2015. Last December, Depomed gained U.S. rights to Cambia from Nautilus Neurosciences Inc....
BioCentury | Dec 23, 2013
Company News

Depomed, Nautilus Neurosciences sales and marketing update

...to Treximet, a combination of sumatriptan and naproxen sodium. Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Nautilus Neurosciences Inc....
BioCentury | Dec 19, 2013
Company News

Depomed jumps on U.S. acquisition of migraine drug

...late Tuesday that it gained U.S. rights to migraine drug Cambia diclofenac oral solution from Nautilus Neurosciences Inc....
BioCentury | Oct 15, 2012
Company News

Stellar Pharmaceuticals sales and marketing update

...2010, Tribute received an exclusive license to develop and commercialize the product in Canada from Nautilus Neurosciences Inc....
BioCentury | Apr 2, 2012
Clinical News

Cambia diclofenac regulatory update

...Co. Ltd. (Nagoya, Japan) in 2009 (see BioCentury, June 29, 2009 & Nov. 22, 2010). Nautilus Neurosciences Inc....
BioCentury | Nov 14, 2011
Company News

Nautilus Neurosciences board of directors update

Nautilus Neurosciences Inc. , Bedminster, N.J. Business: Neurology Appointed: Peter Lankau as executive chairman, formerly CEO of Logical Therapeutics Inc. WIR Staff...
BioCentury | Nov 22, 2010
Company News

Nautilus Neurosciences Inc., Tribute Pharmaceuticals sales and marketing update

...Ltd. (Nagoya, Japan) last year. Financial terms were not disclosed (see BioCentury, Dec. 21, 2009). Nautilus Neurosciences Inc....
BioCentury | Oct 11, 2010
Company News

Mission Pharmacal, Nautilus Neurosciences sales and marketing update

...see BioCentury, Dec. 21, 2009 & June 14). Mission Pharmacal Co. , San Antonio, Texas Nautilus Neurosciences Inc....
BioCentury | Jun 14, 2010
Company News

Nautilus Neurosciences Inc., Kowa sales and marketing update

...last year. Kowa is eligible for milestones under the deal (see BioCentury, Dec. 21, 2009). Nautilus Neurosciences Inc....
BioCentury | Dec 21, 2009
Company News

Nautilus Neurosciences Inc., Kowa deal

...dyslipidemia. Robert W. Baird & Co. advised Kowa (see BioCentury, June 29 & Aug. 10). Nautilus Neurosciences Inc....
Items per page:
1 - 10 of 10
BioCentury | Feb 17, 2014
Analyst Picks & Changes

Analyst picks & changes

...in 2014 and $37M in 2015. Last December, Depomed gained U.S. rights to Cambia from Nautilus Neurosciences Inc....
BioCentury | Dec 23, 2013
Company News

Depomed, Nautilus Neurosciences sales and marketing update

...to Treximet, a combination of sumatriptan and naproxen sodium. Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Nautilus Neurosciences Inc....
BioCentury | Dec 19, 2013
Company News

Depomed jumps on U.S. acquisition of migraine drug

...late Tuesday that it gained U.S. rights to migraine drug Cambia diclofenac oral solution from Nautilus Neurosciences Inc....
BioCentury | Oct 15, 2012
Company News

Stellar Pharmaceuticals sales and marketing update

...2010, Tribute received an exclusive license to develop and commercialize the product in Canada from Nautilus Neurosciences Inc....
BioCentury | Apr 2, 2012
Clinical News

Cambia diclofenac regulatory update

...Co. Ltd. (Nagoya, Japan) in 2009 (see BioCentury, June 29, 2009 & Nov. 22, 2010). Nautilus Neurosciences Inc....
BioCentury | Nov 14, 2011
Company News

Nautilus Neurosciences board of directors update

Nautilus Neurosciences Inc. , Bedminster, N.J. Business: Neurology Appointed: Peter Lankau as executive chairman, formerly CEO of Logical Therapeutics Inc. WIR Staff...
BioCentury | Nov 22, 2010
Company News

Nautilus Neurosciences Inc., Tribute Pharmaceuticals sales and marketing update

...Ltd. (Nagoya, Japan) last year. Financial terms were not disclosed (see BioCentury, Dec. 21, 2009). Nautilus Neurosciences Inc....
BioCentury | Oct 11, 2010
Company News

Mission Pharmacal, Nautilus Neurosciences sales and marketing update

...see BioCentury, Dec. 21, 2009 & June 14). Mission Pharmacal Co. , San Antonio, Texas Nautilus Neurosciences Inc....
BioCentury | Jun 14, 2010
Company News

Nautilus Neurosciences Inc., Kowa sales and marketing update

...last year. Kowa is eligible for milestones under the deal (see BioCentury, Dec. 21, 2009). Nautilus Neurosciences Inc....
BioCentury | Dec 21, 2009
Company News

Nautilus Neurosciences Inc., Kowa deal

...dyslipidemia. Robert W. Baird & Co. advised Kowa (see BioCentury, June 29 & Aug. 10). Nautilus Neurosciences Inc....
Items per page:
1 - 10 of 10